The Diversified Core
Three hundred million Americans on municipal water. EPA-designated carcinogen. Cancer injury values among the highest in the file. The anchor position.
Workplace sterilization gas exposure. Strong causation science. Grossly underadvertised relative to its litigation position. An early mover window that will not stay open.
Revision cases specifically. Mature defendant set. Well-documented injury pathway. Provides near-term resolution balance against the emerging positions.
Highest case value score in the entire TortIntel database. Catastrophic organ failure injuries against a Merck defendant with deep reserves. Pre-verdict window is open now.
MDL 3047 bellwether advancing. Meta, TikTok, Snapchat defendants with trillion-dollar balance sheets. Plaintiff identification improving every quarter.
Tens of millions of GLP-1 users. Gastroparesis injuries severe and documentable. Novo Nordisk defendant depth. Science building toward a clear causation standard.
The only position in this portfolio with six-figure validated case volume behind it. Proven plaintiff identification at scale. The volume anchor in a portfolio of value plays.
FDA black box warning issued. No verdicts yet — litigation is pre-repricing. Indivior defendant. Strong causation. Requires experienced intake management to perform as modeled.
Most mass tort analysts make the same mistake: they chase the case everyone is already talking about. By the time Roundup is on the cover of Law360, the plaintiff pool is picked over and the only attorneys making money are the ones who got in three years ago. Portfolio 1 is built on a different principle — diversification across four independent dimensions that most litigation analysts never think about simultaneously.
Category diversification protects against macro shocks. A single regulatory reversal, a single adverse Daubert ruling, a single bankruptcy filing can devastate a single-category portfolio. Portfolio 1 spreads across environmental, pharmaceutical, medical device, and tech sectors. A setback in one holding does not move the others.
Stage diversification creates a return curve, not a lottery ticket. The litigation tracker above makes this visual. Transvaginal Mesh is in Stage 4 maturation — cases actively resolving with validated values. PFAS, Social Media, EtO, and Suboxone are Stage 3 active litigation — MDL infrastructure built, bellwethers approaching. Keytruda, Ozempic, and Video Game are Stage 2 formation — early enough that the market has not fully priced them. No single time horizon. No waiting five years for everything to resolve at once.
Defendant depth is non-negotiable. Every position in Portfolio 1 faces a defendant with the balance sheet to pay. Merck. Novo Nordisk. Meta. Every one of them has the reserves to resolve at scale. A case against a defendant who files bankruptcy is not a case. It is a claims process.
The fourth dimension is one no other platform publishes. The Jacob Score incorporates plaintiff availability — how findable cases are in the real advertising market — weighted at 40% of the composite. One position in this portfolio has been validated at six-figure case volume. That is not a projection. That is a data point. The market will eventually price that advantage away. It has not yet.
We built the intelligence. We run the advertising. Now you can have both.
Mass Tort Ad Agency manages more Facebook advertising spend for plaintiff attorneys than any firm in the country. Every tort in this portfolio was scored using our real intake market data — because we're already running cases in most of them.
PFAS. Video Game. Social Media. EtO. Suboxone. Ozempic. If you want signed retainers in the torts you just read about, we know exactly how to find them — at the CPL floors that won't hold once the market catches up.